Clinical trial · Interventional
Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis
Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project
NCT00879879CI-TRIAL-00050177completedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Losartan may be effective in treating patients with idiopathic pulmonary fibrosis. PURPOSE: This clinical trial is studying the side effects of losartan and to see how well it works in treating patients with idiopathic pulmonary fibrosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Precancerous Condition | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| losartan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Losartan
- description
- 50 mg tablets of losartan taken daily by mouth for 1 year
- interventionNames
- Drug: losartan
Primary outcomes (1)
- measure
- Number of Participants With Stable or Improved Forced Vital Capacity (FVC) Response at 1 Year
- timeFrame
- 1 year
- description
- Forced vital capacity (FVC) must be \>= 50% at baseline. Stable FVC response is defined as a -5% change in FVC from baseline up to a +5% change from baseline. Improved FVC response is defined as 5% or greater increase in the predicted value of FVC on pulmonary function testing following 12 months of treatment.
Secondary outcomes (4)
- measure
- Number of Participants With Stable, Improved, or Deteriorated Diffusion Capacity of Carbon Monoxide (DLCO) at 1 Year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
INCLUSION CRITERIA: * Age \> 21 years * Diagnosis of idiopathic pulmonary fibrosis * Patients taking Coumadin and/or N-acetylcysteine may participate in the study * Baseline forced vital capacity (FVC) must be greater than or equal to 50% * Baseline 6 minute walk test distance walked must be greater than or equal to 200 meters not requiring greater than 6 lpm of oxygen EXCLUSION CRITERIA: * Pregnant, intending to become pregnant or breastfeeding * Current or previous smoker of cigarettes or marijuana that recently quit within the last 6 months prior to enrollment * Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker * Taking losartan or any other angiotensin II receptor blocker * Baseline systolic blood pressure \< 100 mmHg * Currently taking or has taken immunosuppressant agents within the last month such as azathioprine, cyclophosphamide, colchicine and/or prednisone * History of lung transplant * History of kidney failure or liver disease * Inability to attend clinic visits
References
Publications (0)
Data not yet available
No reference posted for this study.